Cancel

Management of Sickle Cell Disease in the Emergency Department: A Case-Based Discussion

Sickle cell disease (SCD) is a painful disease with many life-threatening complications including acute chest syndrome, infections, severe anemia, and venous thromboembolism. Patients with SCD often present to the ED and hence, it is critical for clinicians in the emergency department (ED) to be educated so that they can promptly assess and treat acute sickle cell pain and evaluate and treat associated complications. While there are some current therapies for SCD, novel therapies are presently...
CME Outfitters

Current Challenges and New Opportunities in Hematopoietic Stem Cell Transplant

STATEMENT OF NEED Hematopoietic stem cell transplant is a potentially curative therapy for patients with hematologic malignancies. There are 2 primary types of HSCT: autologous, where the cells are taken from the patient, and allogeneic, where the cells come from a matched sibling donor or an unrelated donor. Advances in HSCT include the introduction of reduced-intensity conditioning regimens that allow transplant in older patients and alternative graft sources that afford a donor for nearl...
i3 Health

Current Standards and Best Practices in the Management of Tumor Lysis Syndrome

STATEMENT OF NEED Tumor lysis syndrome (TLS) is a rare, potentially life-threatening oncologic emergency typically associated with chemotherapy-induced tumor cell death in which potassium, phosphate, and nucleic acids are released into the bloodstream. This release of intracellular materials results in severe metabolic abnormalities such as hyperuricemia and hyperphosphatemia, which may cause acute renal injury, and hypokalemia and hypocalcemia, which may cause seizures, neuromuscular sympt...
i3 Health

New Clinical Perspectives in the Management of Myelofibrosis

STATEMENT OF NEED Myelofibrosis is a rare type of myeloproliferative neoplasm—a heterogenous group of hematopoietic disorders—that affects approximately 13,000 individuals in the United States. As symptoms do not typically manifest in early stages, patients with myelofibrosis often present with advanced disease. The presence of comorbidities precludes most from allogeneic stem cell transplant, the only potentially curative treatment option available. Due to the dearth of effective treat...
i3 Health

Optimizing the Clinical Outcomes of Patients With Immune Thrombocytopenia

STATEMENT OF NEED Immune thrombocytopenia (ITP) is a heterogeneous disorder with variable clinical features that range from asymptomatic thrombocytopenia to bothersome bruising to life-threatening intracranial hemorrhage. The lack of specific diagnostic criteria remains an important unmet need. Bleeding events are the most common clinical manifestation of ITP but are unpredictable with current laboratory testing. Many patients do not exhibit significant bleeding even in the setting of sever...
i3 Health

TTR Amyloidosis

By learning more about the pathophysiology of rare diseases like TTR Amyloidosis, members of the care team who may encounter these patients on their diagnostic journeys can have a profound impact on their ultimate outcomes.
CheckRare

Virtual Tumor Board: Diagnosis and Management of Myelodysplastic Syndromes

STATEMENT OF NEED Myelodysplastic syndromes (MDS) are a group of heterogeneous hematopoietic disorders derived from an abnormal multipotent progenitor cell, characterized by ineffective hematopoiesis, bone marrow failure, and peripheral blood cytopenias. Survival in MDS ranges from a median of 5.3 years in lower-risk patients to as little as 0.8 years in higher-risk patients. Mortality is usually a result of infection, hemorrhage, and/or iron overload secondary to red blood cell transfusion...
i3 Health

Internal Medicine Comprehensive Review and Update 2020

This CME program from the leading clinical faculty of Harvard Medical School and Massachusetts General Hospital provides comprehensive instruction to ensure clinicians are current with the latest evidence and best practices for: • Cardiovascular Medicine • Pulmonary Medicine • Critical Care • Hematology and Oncology • Mind-Body Medicine • Infectious Diseases • Gastroenterology • Endocrinology • Rheumatology • Nephrology • Travel Medicine • Allergy and Immuno...
Harvard Medical School

Shaping the Future of Myeloma Treatment

To help hematologist-oncologists keep pace with new advancements in multiple myeloma therapeutic regimens and management strategies, Shaping the Future of Myeloma Treatment features a roundtable discussion in which a panel of myeloma experts addresses a number of key clinical topics. Learners who participate in these activities will be expected to improve their ability to individualize treatment plans, based on genomics and risk stratification, to achieve durable remission while minimizing tox...
This CME-certified enduring activity is jointly provided by Penn State College of Medicine, RedMedEd, and the Multiple Myeloma Research Foundation.

The University of Chicago Digestive Diseases Review: University of Chicago Medicine & Biological Sciences Specialty Review (SA-CME)

Studying the University of Chicago Digestive Diseases Review will help you to better: • Keep up with the latest advancements regarding the biology and treatment of patients with digestive diseases • Apply new knowledge in GI, hematology, and nutrition with this review in gastroenterology • Integrate current guidelines into daily practice when preventing and managing digestive diseases
CMEInfo

Intensive Review of Internal Medicine

The Acclaimed Clinical Update and Board Review With more than 120 interactive lectures, case discussions, and board preparation sessions, this CME program is the most comprehensive review of internal medicine offered by the clinical faculty of Harvard Medical School. One of the highest-rated Harvard Medical School CME courses, it sold out the last two years, so early registration is advised. It offers accelerated learning: ► For clinicians seeking a practical and comprehensive review ...
Harvard Medical School

13th International Congress on Myeloproliferative Neoplasms

Over the past two decades, this meeting has become a very popular forum for discussion of the treatment of myeloproliferative neoplasms (MPNs), providing timely, relevant and meaningful information to attendees from around the world. Guided by the expertise of the leaders in the field, this Congress offers highly interactive sessions designed to engage participants and provide a state-of-the-art learning experience. The focus this year will be on the most recent updates and debates centered...
Melton Medical Education, LLC

Update in Hospital Medicine 2020

Comprehensive updates, advances, and best practices to optimize inpatient care This 3-day intensive Harvard Medical School CME program, which has sold out for the past 5 years, updates busy practitioners on current, best practices in hospital medicine. Among the highest-rated Harvard CME courses, the curriculum covers over 30 core topics, with an emphasis on practical management of common problems: • Heart failure • Atrial fibrillation • Acute coronary syndromes • Diabetes • EC...
Harvard Medical School

Eradication of Minimal Residual Disease in Multiple Myeloma: The Role and Timing of ASCT

Advances in multiple myeloma (MM) management have equipped oncology health care providers with the tools and strategies for achieving treatment responses in up to 100% of patients, with as many as 80% reaching a complete response (CR). However, achieving a CR does not always predict long-term survival, and most patients ultimately relapse as a result of the persistence of minimal residual disease (MRD) after treatment. MRD cannot be detected with conventional, low-sensitivity evaluation method...
Albert Einstein College of Medicine

The Current Role of Plasma-Derived Therapies for Hemophilia A

Target Audience This accredited activity is designed to address the educational needs of specialists who care for patients with hemophilia A. Learning Objectives Upon completion of this activity, participants should be able to: Summarize best practices in controversial aspects of hemophilia A care Identify the current, evolving, and future roles for plasma-derived FVIII
This activity is jointly provided by Postgraduate Institute for Medicine (PIM) and CMEology.

The Evolving and Future Role of Plasma-Derived Therapies

Target Audience This accredited activity is designed to address the educational needs of specialists who care for patients with hemophilia A. Learning Objectives After completing this activity, the participant should be better able to: Summarize best practices in controversial aspects of hemophilia A care Identify the current, evolving, and future roles for plasma-derived FVIII Apply strategies to prevent and eradicate inhibitors in patients receiving FVIII
This activity is jointly provided by Postgraduate Institute for Medicine (PIM) and CMEology.

The Debate on Eight: Controversies in Contemporary Care for Patients with Hemophilia A - Module 2: The Evolving and Future Role of Plasma-Derived Therapies

This activity encompasses the evolving and future role of plasma-derived therapies including the importance of ADAMTS13 for congenital thrombotic thrombocytopenic purpura, optimal use of plasma-derived FVIII products, and immune tolerance induction in patients with inhibitors. Two faculty take part in a conversation with audio and synchronized slides. For each topic, the faculty members present their position followed by an interactive debate If you have not already participated, please tak...
CMEology

The Debate on Eight: Controversies in Contemporary Care for Patients with Hemophilia A - Module 1: The Current Role of Plasma-Derived Therapies for Hemophilia A

This activity focuses on the current role of plasma-derived therapies for hemophilia. Topics include the importance of FVIII and hemostasis, bone, cardiovascular, and neurologic considerations, prophylaxis and pharmacokinetics, and safety of plasma-derived products including viral transmission versus recombinant inhibitor development. Two faculty take part in a conversation with audio and synchronized slides. For each topic, the faculty members present their position followed by an interactive...
CMEology

Current Obstacles in Myeloma Management: Debating the Evidence

ACTIVITY DESCRIPTION The clinical multiple myeloma arena has seen significant advances in treatment, diagnosis, imaging, disease monitoring, and supportive care. The approval of several new agents has led to expanded criteria for earlier-stage diagnosis in some higher-risk patients with smoldering multiple myeloma (SMM), though questions remain regarding optimal treatment of other SMM patients. Treatment advances have improved median survival; nevertheless, prognosis remains poor for some pat...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Exploring Nuances Among Targeted and Immune Checkpoint Therapies in Melanoma: Focus on Mechanisms, BRAF Mutation, and Achieving a Durable Response

The treatment of advanced melanoma has shifted dramatically since the introduction of immune checkpoint inhibitors and BRAF/MEK inhibitors. Now, community oncology clinicians have multiple treatment options for their patients with stage III and IV disease that include both targeted and immunotherapies. However, treatment selection is highly complex, requiring consideration of multiple patient-, disease-, and treatment-related variables. It is therefore critical to provide community oncology cl...
Paradigm Medical Communications, LLC.

Quelling an Internal Civil War: New and Emerging Treatments for Graft-vs-Host Disease

Target Audience This educational activity has been designed for hematologists/oncologists, oncology and hematology fellows, and other members of the oncology care team who need to be aware of recent and emerging advances the prevention and treatment of GvHD. Statement of Need/Program Overview The leading cause of non-relapse post- allogeneic hematopoietic stem cell transplant mortality is GvHD manifesting as immunobiological warfare waged by the donor cells against multiple organ systems ...
The University of Nebraska Medical Center, Center for Continuing Education and Integrity Continuing Education, Inc

MCL Patient Exam in the Era of Targeted Therapies: Workup, Prognosis, Treatment, and Monitoring

The rapid evolution of treatment advances in mantle cell lymphoma (MCL) make treatment a complex and challenging proposition. Though several randomized, controlled trials on the use of targeted agents in MCL have been conducted, there are limited published, randomized data providing definitive guidance on treatment selection, duration of treatment, management of treatment-related toxicities, and disease outcomes across different lines of therapy. This activity has been developed to help cl...
Jointly provide by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd

CLL Patient Exam in the Era of Targeted Therapies: Workup, Prognosis, Treatment, and Monitoring

The rapid evolution of treatment advances in chronic lymphocytic leukemia (CLL) make treatment a complex and challenging proposition. Though several randomized, controlled trials on the use of novel targeted biologic agents in CLL have been conducted, there are limited published, randomized data providing definitive guidance on treatment selection (including drug combinations and sequencing therapy), duration of treatment, management of treatment-related toxicities, and disease outcomes across...
Jointly provide by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd

RME Hot Seat: Prognosis, Treatment Choice, and Risk Management for CLL and MCL

With the emergence of new targeted therapies and new prognostic indicators and goals of treatment, the clinical management of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)—for patients in the frontline and relapsed/refractory settings—has evolved significantly. In this Q&A-based activity, our experts provide practical, evidence-based answers to questions relating to several of the most consequential changes in CLL/MCL patient care, including diagnostic and prognostic...
Jointly provide by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd

Optimizing Targeted Therapies in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

The rapid evolution of treatment advances in mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) make treatment a complex and challenging proposition. Though several randomized, controlled trials on the use of targeted agents in MCL and CLL have been conducted, there are limited published, randomized data providing definitive guidance on treatment selection, duration of treatment, management of treatment-related toxicities, and disease outcomes across different lines of therapy. ...
Jointly provide by Albert Einstein College of Medicine-Montefiore Medical Center and RedMedEd

Board Vitals Family Medicine MOC Re-Certification Question Bank and Review

Board Vitals Family Medicine MOC Re-Certification Question Bank and Review contains over 1500 ABFM and AOBFP Family Medicine MOC targeted review questions. The Board Vitals FM qbank offers questions that are directly relevant to the exam: multiple choice questions (mostly focused around patient scenarios) with a single best answer. Board Vitals Family Medicine MOC Re-Certification Question Bank Features: • Take the exam in review mode or timed mode to simulate real FM exam conditions • ...
Board Vitals

Board Vitals USMLE Step 2 Board Review Questions and Practice Tests

Board Vitals USMLE Step 2 Board Review Questions and Practice Tests • Over 1000 USMLE Step 2 Board Review Questions • 100% Pass Guarantee! • Higher Pass Rate Than The National Average • Individualized Learning Based on Performance
Board Vitals

Board Vitals USMLE Step 3 Board Review Questions

Board Vitals USMLE Step 3 Board Review Questions: • 1200 USMLE Step 3 board review questions • Individualized learning • Ability to flag questions for further review • Question are structured by category • Timed and review modes available • Detailed explanations associated with each question
Board Vitals

Board Vitals Internal Medicine Board Review Question Bank and Study Program

The Board Vitals Internal Medicine Board Review Question Bank and Study Program covers topics from Allergy and Immunology to Pulmonary topics - all of the subjects covered on the Internal Medicine Board Exam.  The bank offers over 1200 questions targeted to the ABIM and ABOIM exams.  The Internal Medicine review is highly interactive, offers high yield questions, and offers related images in a manner similar to the board exams.
Board Vitals

Osler Pathology Online Review

After completing the Osler Pathology Online Review, you will be able to: • Use the evidence-based information and practice tools presented to better formulate differ- ential diagnoses for most clinical scenarios • Effectively apply current practice guidelines published by CAP, ASCP and other major medical and governmental agencies • Recognize common patterns of test results and recommend additional tests, as needed, to characterize the etiology and prognosis of individual patient cond...
Osler Institute

Immunotherapy Collaborative of Oncology Networked Communities (IC-ONC) TeleECHO Session – Biomarkers

Target Audience This initiative is designed to meet the educational needs of oncologists, emergency care physicians, oncology pharmacists, oncology nurses and other healthcare professional involved in the management of patients with cancer who are treated or eligible for treatment with immunotherapy. Program Overview This case-based enduring activity will cover the diagnosis, treatment, and management of patients with cancer who are treated or eligible for treatment with immunotherapy. ...
Med Learning

Guideline Update Series: American Society of Hematology Venous Thromboembolism Guideline Update

Need help staying current on recent changes in clinical practice guidelines? This session is for you! This 30-minute presentation provides a practical review of the American Soceity of Hematology 2018 guidelines for the treatement of venous thromboemboism treatment. Listen to a quick summary of what’s changed and how to apply these changes to patients in your practice.
CEI

RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.